Research Antibodies and Reagents Market by Product (Antibodies {Type [Primary, Secondary]} {Production [mAb, pAb]} {Source [Mouse, Rabbit]} Research Area} Media, Stains, Enzyme) Technology (ELISA, Flow Cytometry), Application - Global Forecast to 2031

The Research Antibodies and Reagents Market was valued at $4.08 billion in 2023. This market is expected to reach $6.77 billion by 2031, from an estimated $4.36 billion in 2024, at a CAGR of 6.5% during the forecast period 2024-2031.

Research Antibodies and Reagents Market Size & Forecast

The research antibodies and reagents market is driven by the rising proteomics and genomics research studies, increase in research funding, increasing R&D investments by pharmaceutical & biotechnology companies, and the growing industry-academia collaboration. However, the high cost and time for the identification and development of potential antibodies hinder the growth of this market.

Furthermore, the growing applications of antibodies in clinical trials and medical research, growing research activities in developing countries, and the growing need for new biomarker identification are expected to generate growth opportunities for the players operating in the research antibodies and reagents market. However, issues related to the quality and stability of research antibodies pose major challenges for market growth.

Growing Genomics and Proteomics Research Activities Drive the Market

Proteomics and genomics-based studies have witnessed an upward trend in the past decade. This is attributable to technological advancements and the need to better understand the genetic and molecular bases of various diseases. Proteomics and genomics have been used for the identification of proteins & genes, their structure & function, and respective modifications in various research areas, mainly in medical research and drug discovery & diagnostics. Currently, researchers are using various antibodies, namely polyclonal, monoclonal, recombinant, and mono-specific antibodies for such studies. This is mainly due to their high target specificity and strong affinity toward target molecule, thereby the understanding of protein and gene expression from localization to specific function of the gene or protein.

In complementation with other new techniques in genomics and proteomics, biomarker identification along with drug development can be performed using antibody-based research. For instance, Novartis AG (Switzerland) conducted a clinical trial for iptacopan monoclonal antibody in adults with paroxysmal nocturnal hemoglobinuria. In April 2023, the company announced detailed results from the Phase III APPOINT-PNH trial of investigational oral monotherapy iptacopan in complement-inhibitor-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH).

Increasing R&D Investments by Pharmaceutical & Biotechnology Companies Drive the Research Antibodies and Reagents Market

Pharmaceutical and biotech companies are heavily investing in research and development with a focus on developing novel drugs, drug molecules, and biologics that utilize primary and secondary antibodies. For instance, according to the PhRMA (Pharmaceutical Research and Manufacturers of America) annual membership survey 2022, the R&D spending of PhRMA member companies in the U.S. pharmaceutical & biopharmaceutical sector reached USD 102.3 billion in 2021, a significant increase over USD 83.0 billion in 2019. Similarly, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), in 2022, the R&D expenditure by pharmaceutical companies in Europe increased to around USD 46,893.3 million (EUR 44,500 million) from USD 45,050.8 million (EUR 39,442 million) in 2020.

As research antibodies enable scientists to study the molecular mechanisms underlying diseases and identify potential therapeutic targets, the growing R&D investments for new drug development are expected to increase the demand for research reagents.

Click here to: Get Free Sample Pages of this Report

Key Findings of the Global Research Antibodies and Reagents Market Study:

In 2024, the Antibodies Segment to Dominate the Research Antibodies and Reagents Market

The large market share of this segment is attributed to the widespread applications of antibodies in medicine and biomedical research for diagnosis, drug development, and disease treatment. Further, the increasing proteomics & genomics-based research, funding for R&D, and rising need for disease-specific biomarkers also contribute to the growth of this segment.

Based on type, the antibodies segment is further segmented into primary antibodies and secondary antibodies. In 2024, the primary antibodies segment is expected to account for the large share of the global research antibodies and reagents market. This growth is attributed to the wide adoption of primary antibodies for both direct and indirect antigen detection due to increasing molecular research, advancements in protein purification techniques, and focus on targeted drug discovery programs.

In 2024, the Flow Cytometry Segment to Dominate the Research Antibodies and Reagents Market

The large market share of this segment is attributed to the extensive research activities by universities and pharmaceutical & biotechnological companies in the area of proteomics & cell-based research. Also, the availability of a wide number of antibody-specific fluorescent tags drives the adoption of antibodies monoclonal antibodies and polyclonal antibodies for flow cytometry applications.

Flow cytometry is used clinically for the diagnosis of leukemia and lymphoma, primary immunodeficiency disorders, enumeration of stem cells in peripheral blood, immune status in patients with HIV infection, post-transplantation rejection episodes, minimal residual disease in cancer, and tissue typing. The research in these disease areas depends on flow cytometry, which uses antibodies and reagents. This technology is preferred for antigen detection due to the flexibility of data acquisition, high speed of measurement (1,000 cells/second), and quick qualitative & quantitative analysis regarding the presence of antigens. Researchers use antibodies to identify specific antibodies for the specific antigens for flow cytometry.

In 2024, the Proteomics Segment to Dominate the Research Antibodies and Reagents Market

Advancements in antibody-based technologies, the availability of protein databases, and a rising focus on biomarker discovery through proteomics research support the highest adoption of research antibodies and reagents for proteomics application.

Proteomic research relies heavily on antibodies to study the expression, localization, modification, and interaction of proteins within biological systems. Research antibodies are utilized to detect and quantify specific proteins of interest in complex biological samples. Techniques such as Western blotting, enzyme-linked immunosorbent assay (ELISA), and immunohistochemistry (IHC) rely on the specific binding of antibodies to target proteins, enabling researchers to analyze protein expression levels in various tissues and cell types.

In 2024, the Pharmaceutical & Biotechnology Companies Segment to Dominate the Research Antibodies and Reagents Market

The large market share of the segment is attributed to the heavy R&D investments by pharmaceutical & biotechnology companies toward drug discovery, target identification, and drug development, the growing demand for precision diagnostics, and growing activities for biologics development & manufacturing.

Pharmaceutical & biotechnology companies are actively engaging in drug discovery and development processes, where research antibodies play a crucial role. These companies utilize antibodies to identify and validate drug targets, assess the efficacy and safety of drug candidates, and develop companion diagnostics for personalized medicine.

Asia Pacific: Fastest Growing Market

In 2024, North America is expected to account for the largest share of the global research antibodies and reagents market. However, Asia-Pacific is slated to register the highest CAGR during the forecast period. The high growth of the research antibodies and reagents market in Asia-Pacific is attributed to the growing pharmaceutical and biotech industry, supportive government initiatives, a large number of clinical trials conducted in the Asia-Pacific region, and the growing demand for biologics for the treatment of chronic & infectious diseases.

Research Antibodies and Reagents Market: Key Companies

The report includes a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments in leading industry market players over the past three years 2021–2024. The key players operating in the global research antibodies and reagents market are Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann La-Roche AG (Switzerland), Agilent Technologies, Inc. (U.S.), Becton, Dickinson and Company (U.S.), PerkinElmer, Inc. (U.S.), GenScript Biotech Corporation (U.S.), Bio-Techne Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Santa Cruz Biotechnology, Inc. (U.S.), BioLegend, Inc. (U.S.), Abcam Plc (U.K.), OriGene Technologies, Inc. (U.S.), and Cell Signaling Technology, Inc. (U.S.).

Research Antibodies and Reagents Market Report Summary:

Key questions answered in the report: